메뉴 건너뛰기




Volumn 49, Issue 4, 2016, Pages 1360-1368

The EGFR pathway is involved in the regulation of PDL1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer

Author keywords

Epidermal growth factor receptor; IL 6; JAK; Non small cell lung cancer; Programmed death ligand 1; STAT3

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 6; JANUS KINASE; PROGRAMMED DEATH 1 LIGAND 1; STAT3 PROTEIN; CD274 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; STAT3 PROTEIN, HUMAN;

EID: 84990050235     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3632     Document Type: Article
Times cited : (249)

References (36)
  • 2
    • 84883013481 scopus 로고    scopus 로고
    • Management of non-small-cell lung cancer: Recent developments
    • Reck M, Heigener DF, Mok T, Soria JC and Rabe KF: Management of non-small-cell lung cancer: Recent developments. Lancet 382: 709-719, 2013.
    • (2013) Lancet , vol.382 , pp. 709-719
    • Reck, M.1    Heigener, D.F.2    Mok, T.3    Soria, J.C.4    Rabe, K.F.5
  • 4
    • 84924577386 scopus 로고    scopus 로고
    • Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumorinfiltrating T cells and the status of oncogenic drivers
    • Kim MY, Koh J, Kim S, Go H, Jeon YK and Chung DH: Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumorinfiltrating T cells and the status of oncogenic drivers. Lung Cancer 88: 24-33, 2015.
    • (2015) Lung Cancer , vol.88 , pp. 24-33
    • Kim, M.Y.1    Koh, J.2    Kim, S.3    Go, H.4    Jeon, Y.K.5    Chung, D.H.6
  • 5
    • 84857502654 scopus 로고    scopus 로고
    • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial
    • Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
    • Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, et al; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246, 2012.
    • (2012) Lancet Oncol , vol.13 , pp. 239-246
    • Rosell, R.1    Carcereny, E.2    Gervais, R.3    Vergnenegre, A.4    Massuti, B.5    Felip, E.6    Palmero, R.7    Garcia-Gomez, R.8    Pallares, C.9    Sanchez, J.M.10
  • 6
    • 84898748420 scopus 로고    scopus 로고
    • Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: A meta-analysis
    • Lee JK, Hahn S, Kim DW, Suh KJ, Keam B, Kim TM, Lee SH and Heo DS: Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: A meta-analysis. JAMA 311: 1430-1437, 2014.
    • (2014) JAMA , vol.311 , pp. 1430-1437
    • Lee, J.K.1    Hahn, S.2    Kim, D.W.3    Suh, K.J.4    Keam, B.5    Kim, T.M.6    Lee, S.H.7    Heo, D.S.8
  • 10
    • 84931054440 scopus 로고    scopus 로고
    • The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
    • Tang Y, Fang W, Zhang Y, Hong S, Kang S, Yan Y, Chen N, Zhan J, He X, Qin T, et al: The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget 6: 14209-14219, 2015.
    • (2015) Oncotarget , vol.6 , pp. 14209-14219
    • Tang, Y.1    Fang, W.2    Zhang, Y.3    Hong, S.4    Kang, S.5    Yan, Y.6    Chen, N.7    Zhan, J.8    He, X.9    Qin, T.10
  • 12
    • 84896713991 scopus 로고    scopus 로고
    • The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone
    • Afreen S and Dermime S: The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone. Hematol Oncol Stem Cell Ther 7: 1-17, 2014.
    • (2014) Hematol Oncol Stem Cell Ther , vol.7 , pp. 1-17
    • Afreen, S.1    Dermime, S.2
  • 13
    • 84921308811 scopus 로고    scopus 로고
    • The PD-1/PD-L1 pathway: Biological background and clinical relevance of an emerging treatment target in immunotherapy
    • Muenst S, Soysal SD, Tzankov A and Hoeller S: The PD-1/PD-L1 pathway: Biological background and clinical relevance of an emerging treatment target in immunotherapy. Expert Opin Ther Targets 19: 201-211, 2015.
    • (2015) Expert Opin Ther Targets , vol.19 , pp. 201-211
    • Muenst, S.1    Soysal, S.D.2    Tzankov, A.3    Hoeller, S.4
  • 14
    • 84928774156 scopus 로고    scopus 로고
    • The future of immune checkpoint therapy
    • Sharma P and Allison JP: The future of immune checkpoint therapy. Science 348: 56-61, 2015.
    • (2015) Science , vol.348 , pp. 56-61
    • Sharma, P.1    Allison, J.P.2
  • 16
    • 33645506849 scopus 로고    scopus 로고
    • Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor
    • Alvarez JV, Greulich H, Sellers WR, Meyerson M and Frank DA: Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 66: 3162-3168, 2006.
    • (2006) Cancer Res , vol.66 , pp. 3162-3168
    • Alvarez, J.V.1    Greulich, H.2    Sellers, W.R.3    Meyerson, M.4    Frank, D.A.5
  • 19
    • 33749316418 scopus 로고    scopus 로고
    • The epidermal growth factor receptor pathway: A model for targeted therapy
    • Scaltriti M and Baselga J: The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res 12: 5268-5272, 2006.
    • (2006) Clin Cancer Res , vol.12 , pp. 5268-5272
    • Scaltriti, M.1    Baselga, J.2
  • 20
    • 79957492069 scopus 로고    scopus 로고
    • American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy
    • Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA and Giaccone G: American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29: 2121-2127, 2011.
    • (2011) J Clin Oncol , vol.29 , pp. 2121-2127
    • Keedy, V.L.1    Temin, S.2    Somerfield, M.R.3    Beasley, M.B.4    Johnson, D.H.5    McShane, L.M.6    Milton, D.T.7    Strawn, J.R.8    Wakelee, H.A.9    Giaccone, G.10
  • 21
    • 31444451661 scopus 로고    scopus 로고
    • Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gammainduced upregulation of B7-H1 (CD274)
    • Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM, Oh S, Shin JG, Yao S, Chen L, et al: Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gammainduced upregulation of B7-H1 (CD274). FEBS Lett 580: 755-762, 2006.
    • (2006) FEBS Lett , vol.580 , pp. 755-762
    • Lee, S.J.1    Jang, B.C.2    Lee, S.W.3    Yang, Y.I.4    Suh, S.I.5    Park, Y.M.6    Oh, S.7    Shin, J.G.8    Yao, S.9    Chen, L.10
  • 25
    • 84923090821 scopus 로고    scopus 로고
    • Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma
    • Ritprajak P and Azuma M: Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol 51: 221-228, 2015.
    • (2015) Oral Oncol , vol.51 , pp. 221-228
    • Ritprajak, P.1    Azuma, M.2
  • 26
  • 27
    • 34347400169 scopus 로고    scopus 로고
    • Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
    • Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, Saudemont A and Quesnel B: Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110: 296-304, 2007.
    • (2007) Blood , vol.110 , pp. 296-304
    • Liu, J.1    Hamrouni, A.2    Wolowiec, D.3    Coiteux, V.4    Kuliczkowski, K.5    Hetuin, D.6    Saudemont, A.7    Quesnel, B.8
  • 31
    • 84935004492 scopus 로고    scopus 로고
    • EGFR-TKI downregulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-B
    • Lin K, Cheng J, Yang T, Li Y and Zhu B: EGFR-TKI downregulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-B. Biochem Biophys Res Commun 463: 95-101, 2015.
    • (2015) Biochem Biophys Res Commun , vol.463 , pp. 95-101
    • Lin, K.1    Cheng, J.2    Yang, T.3    Li, Y.4    Zhu, B.5
  • 32
    • 77957664158 scopus 로고    scopus 로고
    • Programmed death-1 upregulation is correlated with dysfunction of tumorinfiltrating CD8+ T lymphocytes in human non-small cell lung cancer
    • Zhang Y, Huang S, Gong D, Qin Y and Shen Q: Programmed death-1 upregulation is correlated with dysfunction of tumorinfiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 7: 389-395, 2010.
    • (2010) Cell Mol Immunol , vol.7 , pp. 389-395
    • Zhang, Y.1    Huang, S.2    Gong, D.3    Qin, Y.4    Shen, Q.5
  • 33
    • 84873666114 scopus 로고    scopus 로고
    • Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: A 5-year-follow-up study
    • Chen YB, Mu CY and Huang JA: Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: A 5-year-follow-up study. Tumori 98: 751-755, 2012.
    • (2012) Tumori , vol.98 , pp. 751-755
    • Chen, Y.B.1    Mu, C.Y.2    Huang, J.A.3
  • 34
    • 80052476869 scopus 로고    scopus 로고
    • High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
    • Mu CY, Huang JA, Chen Y, Chen C and Zhang XG: High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 28: 682-688, 2011.
    • (2011) Med Oncol , vol.28 , pp. 682-688
    • Mu, C.Y.1    Huang, J.A.2    Chen, Y.3    Chen, C.4    Zhang, X.G.5
  • 35
    • 84964792419 scopus 로고    scopus 로고
    • Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2
    • Robert L, Ribas A and Hu-Lieskovan S: Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2 Semin Immunol 28: 73-80, 2016.
    • (2016) Semin Immunol , vol.28 , pp. 73-80
    • Robert, L.1    Ribas, A.2    Hu-Lieskovan, S.3
  • 36
    • 84915750492 scopus 로고    scopus 로고
    • Universes collide: Combining immunotherapy with targeted therapy for cancer
    • Wargo JA, Cooper ZA and Flaherty KT: Universes collide: Combining immunotherapy with targeted therapy for cancer. Cancer Discov 4: 1377-1386, 2014.
    • (2014) Cancer Discov , vol.4 , pp. 1377-1386
    • Wargo, J.A.1    Cooper, Z.A.2    Flaherty, K.T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.